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Vancomycin-resistant enterococci (VRE) are major nosocomial pathogens worldwide. While antimicrobial pressure promotes nosocomial colonization with VRE, prolonged exposure to vancomycin may foster the transition from vancomycin resistance to dependence ([@B1]). Enterococci showing growth on medium containing 6 µg/ml vancomycin and an MIC of \>8 µg/ml are considered vancomycin resistant. Strains unable to grow in the absence of 6 µg/ml vancomycin, despite multiple subcultures, are considered vancomycin dependent ([@B1]). Vancomycin-dependent enterococcus (VDE) was first described in 1993 ([@B2], [@B3]). To our knowledge, only twenty-five cases of VDE have been described worldwide so far ([@B4]).

We report here the draft genome of a VRE/VDE isolate obtained in Austria in 2007 from an oncology patient 1 month after cessation of teicoplanin therapy ([@B5]). The described strain of VDE showed resistance to penicillin (MIC, 64 µg/ml), ampicillin (MIC, 128 µg/ml), amoxicillin-clavulanate (amoxicillin MIC, \>256 µg/ml), erythromycin (MIC, 8 µg/ml), clindamycin (MIC, 8 µg/ml), ciprofloxacin (MIC, \>2 µg/ml), moxifloxacin (MIC, \>2 µg/ml), fusidic acid (MIC, 4 µg/ml), and low-level resistance to gentamicin (MIC, 32 µg/ml) when tested according to Clinical and Laboratory Standards Institute (CLSI) standards ([@B6]). The strain was susceptible to quinupristin-dalfopristin (MIC, \<0.5 µg/ml), oxytetracycline (MIC, \<0.5 µg/ml), linezolid (MIC, 2 µg/ml), chloramphenicol (MIC, 8 µg/ml), and mupirocin (MIC, 2 µg/ml). The strain showed intermediate resistance to teicoplanin when tested on Mueller-Hinton agar (bioMérieux, Marcy l'Etoile, France) using a 30-µg teicoplanin disc (Oxoid, Basingstoke, United Kingdom) or a teicoplanin Epsilon test strip (AB Biodisk, Solna, Sweden) (MIC, 8 µg/ml). It also showed partial teicoplanin dependence, i.e., it grew in the area of low concentration of teicoplanin (0.016 to 6 µg/ml) but was inhibited in the area with high teicoplanin concentrations (8 to 256 µg/ml). The strain showed high-level resistance to vancomycin (MIC, \>256 µg/ml) and complete vancomycin dependence when tested on Mueller-Hinton agar (bioMérieux) with a 30-µg vancomycin disk (Oxoid) or a vancomycin Epsilon test strip (AB Biodisk). The strain also showed *in vitro* reversion to vancomycin-nondependent vancomycin-resistant *Enterococcus faecium* mutants.

The MagAttract high-molecular-weight (HMW) DNA kit (Qiagen, Hilden, Germany) was used to isolate genomic DNA from overnight cultures grown on Mueller-Hinton agar plates (bioMérieux) with a 30-µg vancomycin disk (Oxoid) and a 30-µg teicoplanin disk (Oxoid). The fragment library was prepared using the Nextera XT kit (Illumina, Inc., San Diego, CA) and 1 ng of genomic DNA. Paired-end sequencing (2 × 300 bp) was performed on a MiSeq (Illumina, Inc.), generating 1,365,744 reads from 333,173,006 unassembled nucleotides. Raw reads were *de novo* assembled into a draft genome using Velvet version 1.1.04 ([@B7]). Contigs were filtered for a minimum coverage of 5 and minimum length of 200 bp, which resulted in 232 contigs with a total of 2,949,766 nucleotides at a coverage of 95-fold. A total of 2,953 genes, 2,878 coding sequences, 95 pseudogenes, 7 rRNA genes, and 64 tRNA genes were identified using the NCBI Prokaryotic Genome Annotation Pipeline (<http://www.ncbi.nlm.nih.gov/genome/annotation_prok/>).
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This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession no. [LQRS00000000](LQRS00000000). The version described in this paper is the first version, LQRS01000000.
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